MDMA-Assisted PTSD Therapy

MAPS-model protocol simulator for MDMA-assisted psychotherapy.

Current Stage

—

—

Amygdala fear response

—

Therapeutic window

—

Current CAPS-5

—

Response trajectory

—

MDMA Dosing Session1

Baseline CAPS-5 Severity50

Amygdala (fear circuit)

Therapeutic window pulse

Therapist dyad presence

Trauma memory node

CAPS-5 trend line

Scroll for details

Preparatory Non-Drug Therapy Sessions

Placeholder: two non-drug sessions build the therapeutic alliance first.

2–3: Prep sessions (Placeholder short caption)
90 min: Session length (Placeholder short caption)
Dyad: Co-therapist model (Placeholder short caption)
MAPS: Protocol source (Placeholder short caption)

Building trust before dosing

Placeholder: preparatory sessions establish rapport and set intentions.

First MDMA Dosing Session

Placeholder: an 8-hour supervised session with a divided dose.

80–120mg: Initial dose (Placeholder short caption)
40–60mg: Booster dose (Placeholder short caption)
~8 hrs: Session duration (Placeholder short caption)
Continuous: Monitoring (Placeholder short caption)

Supervised dosing conditions

Placeholder: vitals and affect monitored throughout the session.

Reduced Fear Response Window

Placeholder: amygdala reactivity drops, easing fear-based avoidance.

↓ reduced: Amygdala activity (Placeholder short caption)
↑ increased: Trust / bonding (Placeholder short caption)
↓ reduced: Defensiveness (Placeholder short caption)
~4–6 hrs: Window duration (Placeholder short caption)

A neurobiological window opens

Placeholder: reduced fear response allows safer trauma engagement.

Trauma Processing With Therapist

Placeholder: patient revisits traumatic memories with guided support.

Guided: Processing mode (Placeholder short caption)
3 per dose: Integration sessions (Placeholder short caption)
Active: Memory reconsolidation (Placeholder short caption)
Non-directive: Therapist role (Placeholder short caption)

Working through trauma memories

Placeholder: memories are revisited and reframed with support.

Placeholder key insight: processing occurs within the open window.

CAPS-5 Score Improvement Across Sessions

Placeholder: PTSD symptom severity declines across three sessions.

~50–60%: CAPS-5 reduction (Placeholder short caption)
~67%: Remission rate (Placeholder short caption)
12 months: Follow-up (Placeholder short caption)
Phase 3: Trial phase (Placeholder short caption)

Trajectory of symptom relief

Placeholder: scores trend downward with each processed session.